Achieved in vivo editing of liver cells in non-human primates and in vivo delivery to two additional cell types in humanized mice Strategic priorities through 2027 include: submit at least one IND/CTA ...

HealthEquity will discuss these results and estimates during a presentation by Scott Cutler, President and CEO, Steve Neeleman, Vice Chair and Founder and James Lucania, EVP and CFO, at the 43 rd ...

The first selective Fatty Acid Binding Protein 5 inhibitor safely administered to human subjects ...

The shipment follows regulatory approvals for direct importation and positions AutoMax to begin marketing and sales activities for JAC Motors vehicles across Israel.

VIVUS will be discussing its significant 2024 momentum during the J.P. Morgan Healthcare Conference, with an emphasis on what we as a company aim to achieve during the coming months around our novel ...

Wave received supportive initial feedback from FDA, who recognize the severity of HD and are receptive to and engaged with Wave regarding a potential pathway to accelerated approval. FDA is open to ...

U.S. revenue between $158.2 - $158.4 million, representing ~21% growth ...

Aaron Green, Chief Executive Officer, stated, “We are pleased to have now achieved compliance with the Nasdaq listing rules. This accomplishment will enable us to focus in 2025 on growing our revenue ...

NeurAxis's robust sales growth and disciplined cost management have set the stage for achieving cash flow breakeven in 2026. Notably, recent investments from life science-focused funds have bolstered ...

Lipozem: Cellular Swelling When toxins—such as pesticides, preservatives, and other chemicals—enter the body, they can attack ...

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today ...

The Company’s fourth quarter and full-year 2024 financial and operational results are preliminary and are subject to the completion of the Company’s 2024 audit. Audited full-year 2024 and unaudited ...